Matthew Keller
Stock Analyst at HC Wainwright & Co.
(n/a)
# 4,737
Out of 5,139 analysts
10
Total ratings
11.11%
Success rate
-30.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IFRX InflaRx | Reiterates: Buy | $6 | $1.00 | +500.00% | 2 | Dec 30, 2025 | |
| GALT Galectin Therapeutics | Maintains: Buy | $6 → $11 | $3.04 | +261.84% | 2 | Dec 17, 2025 | |
| SXTP 60 Degrees Pharmaceuticals | Assumes: Buy | $6 | $0.61 | +883.61% | 1 | Nov 14, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $10.44 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $2.65 | +1,069.81% | 2 | Sep 30, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.68 | +134.38% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.14 | +1,128.07% | 1 | Aug 15, 2025 |
InflaRx
Dec 30, 2025
Reiterates: Buy
Price Target: $6
Current: $1.00
Upside: +500.00%
Galectin Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $6 → $11
Current: $3.04
Upside: +261.84%
60 Degrees Pharmaceuticals
Nov 14, 2025
Assumes: Buy
Price Target: $6
Current: $0.61
Upside: +883.61%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $10.44
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $2.65
Upside: +1,069.81%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.68
Upside: +134.38%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $1.14
Upside: +1,128.07%